Anticoagulants II

The lecture covers the modulation of the hemostasis and coagulation systems through various pharmacological agents. Hemostasis is the process that prevents and stops bleeding, and coagulation refers specifically to the formation of blood clots. Various drugs are used to manage and influence these processes, particularly when a patient has conditions that predispose them to excessive bleeding or clotting. Primary categories of drugs discussed include:

• Anticoagulants: These are medications that prevent blood from coagulating (clotting) too much. Two types that are commonly used are Heparin and Low Molecular Weight Heparins (LMWHs).

  • Heparin: A fast-acting injectable anticoagulant that is used in hospitals.

  • Low Molecular Weight Heparins (LMWHs): These have better properties for certain patients, and they are easier to use compared to unfractionated heparin.   

• Warfarin: This is identified as one of the most commonly prescribed anticoagulants in the United States. Unlike heparin, warfarin is taken orally and works through a different mechanism.

• Direct Thrombin Inhibitors: A class of anticoagulants that inhibit thrombin, an important enzyme in the clotting process.

• Direct Factor $X$ Inhibitors: These target factor $X$ directly and work to inhibit blood clot formation.

• Fibrinolytics: These drugs help dissolve blood clots that have already formed, which is essential in conditions like stroke or heart attack.

• Antiplatelet agents: These prevent platelets in the blood from sticking together to form clots.

Characteristics of an Ideal Anticoagulant Drug

An ideal anticoagulant would achieve two primary goals simultaneously:

• Prevent pathologic thrombosis: This means stopping clots from forming inappropriately, which can cause serious health issues like heart attacks or strokes.

• Limit reperfusion injury: This involves preventing new clots from forming after blood flow is restored to an area that has been deprived of oxygen, such as during certain medical procedures.

  • It is important that the body retains the ability to form clots in response to legitimate vascular injuries, which helps control bleeding.

Theoretical mechanism for an ideal drug:

• Theoretically, this could be achieved by blocking the Tissue Factor, which triggers the extrinsic pathway of the coagulation cascade.

  • This would allow the coagulation process to happen in a controlled manner when there is an actual injury, but prevent unwanted clot formation due to the intrinsic pathway, which can lead to conditions like Deep Venous Thrombosis (DVT).

Current Reality:

• Currently, no ideal drug exists that can specifically target only harmful clotting while preserving normal hemostasis (the natural stopping of bleeding). As a result, all existing anticoagulant or anti-fibrinolytic drugs have an increased bleeding risk as their main side effect. Therefore, understanding how these drugs work, their antidotes, and how to monitor patients for complications is crucial.

Heparin and Low Molecular Weight Heparins (LMWH)

• Biological Mechanism:
  These drugs work through a system of negative regulators of the coagulation cascade. In simpler terms, they help slow down the clotting process when necessary. Antithrombin III is the key negative regulator that naturally circulates in the body to prevent clots from forming too quickly. Heparin and LMWHs help enhance the activity of Antithrombin III, increasing its ability to stop Thrombin and Factor $X$, which are both essential in the clotting process.

• Specific Actions of Heparin vs. LMWH:

• Antithrombin III state: Normally, this is inactive when in the bloodstream.

  • LMWH Binding: When LMWH binds to Antithrombin III, it changes shape, enhancing its ability to inhibit clotting factors, especially Factor $X$.

  • Unfractionated Heparin Binding: It's a larger molecule that not only boosts Antithrombin III activity but also locks it in place when it deals with Thrombin. This means unfractionated heparin is more effective at inhibiting Thrombin itself, while LMWHs primarily target Factor $X$.

• Administration and Pharmacokinetics:
  Heparins are not available in pill form; they must be administered by injection (subcutaneously or intravenously). This is why they are primarily used in hospitals. The effects are immediate once they are given, which is beneficial in acute medical settings. Heparin is a type of molecule known as a sulfated glycosaminoglycan, which plays a significant role in its function.

Clinical Applications and Monitoring of Heparin

• Immediate Anticoagulation Uses:

• Myocardial Infarction (MI): Heparin therapy has been proven to significantly decrease mortality rates in heart attack scenarios by at least 20\text{\text{%}}.

  • It helps prevent excessive bloodstream clotting in various medical situations such as during surgeries.

  • In dialysis treatments, Heparin is administered to avoid clot formation during various interventions, especially in patients with kidney failure.

• Duration of Use:
  Typically, heparin is prescribed for short periods, usually ranging from $7$ to $10$ days. If a patient requires longer-term anticoagulation, doctors will switch them over to Warfarin during this time.

• Standardization and Source:
  Unfractionated Heparin is sourced from animal tissues, primarily from cows and pigs. Due to the fact that only a small portion of the harvested substance is actively effective, ensuring consistent dosing can be quite challenging. LMWHs are easier to standardize as they are produced with specific properties.

• Activity Environments:
  Heparin is effective both in vivo (inside living organisms) and in vitro (in blood test tubes). This is because it activates Antithrombin III present in the plasma and prevents clotting in both scenarios.

• Monitoring Requirements:
  It’s essential to monitor heparin’s effects through tests like Partial Thromboplastin Time (PTT), which checks how well the blood clots.

Side Effects, Toxicity, and Heparin-Induced Thrombocytopenia (HIT)

• General Risks:
  Having an increased risk of bleeding is the primary concern when using heparin and LMWH. Injecting it into muscle (IM) is especially dangerous because it can lead to severe internal bleeding.

  • Allergic reactions may develop, particularly since these drugs are derived from animals, with higher rates occurring with bovine (cow) sourced heparin than with porcine (pig) counterparts.

• Heparin-Induced Thrombocytopenia (HIT):
  This condition can occur in about 4\text{\text{%}} of patients taking heparin. It can lead to a paradoxical increase in blood clotting as the body starts consuming platelets quickly, leading to risk for clots and bleeding complications. Signs include a drop in platelet counts which is monitored through repeated blood tests.

  • Reaction sequence: Rapid consumption of key clotting factors creates numerous small clots that can result in significant bleeding.

  • Management: The first step is to stop heparin administration immediately, with direct Factor II (direct thrombin) inhibitors as key treatment.

• Antidote:
  Heparins can be neutralized by a medication called prodomin, which is a basic protein and acts as an antidote to counteract the effect of heparin.

Low Molecular Weight Heparin (LMWH) Specifics

• LMWHs are shorter forms of heparin. This gives them several advantages:

  • Generally, they have better bioavailability (more effective when absorbed) and longer half-lives than unfractionated heparin.

  • LMWHs are easier to standardize, making dosing more straightforward.

  • Usage remains parenteral (injected), meaning no oral forms are available.

  • Monitoring: Instead of using PTT, the effectiveness of LMWH can be measured using anti-Factor $X$ activity due to their predominant inhibition of Factor $X$.

  • Excretion: All heparins, including LMWH, are primarily eliminated from the body through the kidneys (renal excretion).

  • Contraindication: Their high risk of HIT and potential bleeding complications makes them unsuitable for patients who have kidney disease.

Warfarin (Coumadin)

• Mechanism of Action:
  Warfarin is considered an indirect anticoagulant. It works primarily by inhibiting the use of Vitamin K, a crucial nutrient in synthesizing certain clotting factors, including Factors $X$, $VII$, $IX$, and Prothrombin (Factor $II$). Even though these factors are still present in circulation, they are not functional, decreasing the blood’s ability to clot effectively.

• Historical Discovery:
  The origins of Warfarin date back to farmers in Wisconsin who noticed their cattle bleeding after consuming spoiled sweet clover. Scientists isolated Coumadin (the compound that led to Warfarin) and, after further research, it became a medication used clinically starting in the $1940\text{s}$. Initially, it was used as a rat poison due to its effective bleeding risk before being approved for use in humans.

Pharmacokinetics and Administration of Warfarin

• Onset of Action:
  The effects of Warfarin don’t manifest immediately; rather it takes about $48$ to $72$ hours for it to fully take effect. This delay is primarily due to the need for existing clotting factors in the bloodstream to deplete before seeing the anticoagulant effect. Prothrombin has the longest half-life at approximately $60$ hours, which is significant in determining the delay in action.

• Direct vs. Indirect Activity:
  Warfarin’s action occurs in vivo (within a living system) and has no effect when added to blood samples taken for testing (in vitro). This is because it prevents the formation of new clotting factors in the liver.

• Monitoring (PT and INR):
  Warfarin's effectiveness is closely monitored via Prothrombin Time (PT). The International Normalized Ratio (INR) is a standardized way to report PT results, important for consistency across different labs. Typically a normal INR is around $1$, while the therapeutic target for those on Warfarin generally falls between $2-3$.

• Physical Properties:
  Warfarin is a small and lipid-soluble molecule, making it easy to absorb when taken orally. It binds significantly to plasma proteins, which keeps its distribution and elimination patterns distinct from other medications, thus resulting in a long half-life.

• Compliance Advantage:
  Patients find Warfarin advantageous because, due to its long half-life, missing a dose does not immediately affect their coagulation status, which is especially useful when compared to shorter-acting anticoagulants that can have immediate effects.

Clinical Use and Contraindications of Warfarin

• Indications:
  Warfarin is used for longer periods, from weeks to months depending on the rationale. For example, it’s prescribed for:

  • Deep Venous Thrombosis (DVT) prophylaxis.

  • Patients with mechanical heart prosthesis, often to prevent clot formation around the prosthetic valves.

  • Myocardial Infarctions (MIs), particularly for those who have recently had stents inserted.

• Bridging Therapy:
  Since Warfarin also inhibits the synthesis of natural anticoagulants, like Proteins $C$ and $S$, a shorter-term anticoagulant like heparin is often provided at the same time to prevent a temporary increase in clotting risk that could occur if Warfarin is started alone and takes time to influence the levels of these proteins.

• Pregnancy Contraindication:
  Warfarin crosses the placental barrier, presenting significant risks during pregnancy, including fetal bleeding and complications with fetal bone development. As such, it is strictly contraindicated in pregnant women, whereas heparin does not cross the placenta and is generally considered safer, although risks must still be carefully evaluated.

Warfarin Toxicity and Drug Interactions

• Overdose Management:
  Excessive Warfarin intake can cause severe bleeding, and thus management includes:

  • Primary Antidote: Vitamin $K$ can be administered to counteract the overdose effects but takes time as it requires the body to synthesize new clotting factors to see improvement.

  • Immediate Treatment: Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrates (PCC) can replace functional factors right away to manage bleeding faster.

• Pharmacokinetic Interactions (Increased Effect):
  Drugs that affect liver enzymes may increase Warfarin effectiveness, as can drugs that displace Warfarin from plasma protein binding sites, leading to higher concentrations in the bloodstream.

• Pharmacodynamic Interactions (Increased Effect):
  Some medications have a synergistic effect with Warfarin, such as Aspirin and other NSAIDs, increasing bleeding risk by inhibiting normal platelet function. Other contributors include antibiotics that eliminate gut bacteria responsible for Vitamin $K$ production, leading to deficiencies.

• Interactions (Decreased Effect):
  Certain medications, like diuretics, can increase clotting factor concentrations, while hypothyroidism decreases the turnover rate of these factors, leading to reduced warfarin effects.

Comparative Summary: Heparin vs. Warfarin

• Structure/Chemistry:
  Heparin is a larger, acidic polymer, while Warfarin is a smaller, lipid-soluble molecule.

• Antidote:
  Prodomin (basic) for Heparin; Vitamin $K$, FFP, or PCC for Warfarin.

• Route of Administration:
  Heparin is given by injection, while Warfarin is taken orally.

• Site of Action:
  Heparin works directly in the bloodstream, whereas Warfarin works indirectly by affecting the liver.

• Onset of Action:
  Heparin works immediately, while Warfarin takes $48-72$ hours to show full effects.

• Duration/Use:
  Heparin is used for short-term (days), while Warfarin can be used for long-term (weeks/months).

• Pregnancy:
  Heparin can be used during pregnancy, while Warfarin presents risks to the fetus and is strictly contraindicated.